olpadronic acid has been researched along with Bone Cancer in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burton, DW; Deftos, LJ; Geller, J; Hastings, RH; Hillegonds, DJ; Hoffman, RM; Yang, M | 1 |
| Hamdy, NA; Lycklama à Nijeholt, AA; Papapoulos, SE; Pelger, RC; Zwinderman, AH | 1 |
| Berenson, J; Hortobagyi, G; Lipton, A; Major, PP | 1 |
| Keppler, BK; Klenner, T; Krempien, B; Schmähl, D; Wingen, F | 1 |
1 review(s) available for olpadronic acid and Bone Cancer
| Article | Year |
|---|---|
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Double-Blind Method; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid | 2000 |
1 trial(s) available for olpadronic acid and Bone Cancer
| Article | Year |
|---|---|
Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Calcium; Diphosphonates; Follow-Up Studies; Humans; Hydroxyproline; Injections, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Osteoblasts; Pain; Prostatic Neoplasms | 1998 |
2 other study(ies) available for olpadronic acid and Bone Cancer
| Article | Year |
|---|---|
The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Calcium; Cell Line, Tumor; Diphosphonates; Disease Progression; Glycoproteins; Green Fluorescent Proteins; Humans; Male; Mice; Mice, Nude; Osteoprotegerin; Pamidronate; Parathyroid Hormone-Related Protein; Prostatic Neoplasms; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Time Factors; Treatment Outcome; Xenograft Model Antitumor Assays | 2006 |
Anticancer-agent-linked phosphonates with antiosteolytic and antineoplastic properties: a promising perspective in the treatment of bone-related malignancies?
Topics: Animals; Bone and Bones; Bone Neoplasms; Carcinoma 256, Walker; Diphosphonates; Drug Evaluation, Preclinical; Organophosphorus Compounds; Organoplatinum Compounds; Osteosarcoma; Pamidronate; Rats | 1990 |